Wen ZHOU

Professional Title: Professor

Education: PhD

Supervisor Category: Doctoral Supervisor

Research Fields: Pharmaceutical Chemistry

1. Introduction

Zhou Wen is a professor and a doctoral mentor in Pharmaceutical Chemistry, and received Ph.D. from Shanghai Jiao Tong University in 2008, and is currently the chief scientist of the Animal anti-infective Drug and Microbial Resistance group, and the director of the Key Laboratory of Veterinary Chemical Drugs and Pharmacy of Ministry of Agriculture and Rural Affairs. He was ever selected as a talent of Guangzhou City, SMC-Morning Star Program of Shanghai Jiao Tong University, and Young Xinglin Scholar of Guangzhou University of Traditional Chinese Medicine.  He is currently on the editorial board of Frontiers in Pharmacology, Veterinary Sciences, Natural Products Research and Development, respectively. He is also the doctoral mentor of Shandong University, the master mentor of Wannan Medical College, the master mentor of Shanghai University of Applied Technology, the council member of Shanghai Feed and Veterinary Industry Association, and the deputy director of Shanghai Pet Food and Drug Professional Committee.

He has been long engaged in drug design and synthesis, druggability evaluation, drug innovation and their key common technology development. He has completed the druggability evaluation of candidate carbohydrate drug HSCD-54 and anthraquinone NR-20, as well as the construction of heparan sulfate microarrays for commercialization, and mainly participated in the preclinical drug evaluation of shikonin oxime DMSK-20. He has presided over and participated in 25 projects including Joint Foundation of National Natural Science Foundation, National Natural Science Foundation, Key projects of National Natural Science Foundation, NIH, FDA, etc. He has trained 3 doctors, 10 masters, and 2 postdoctoral fellows. He has published 95 high-quality papers including 85 SCI, and 5 textbooks and works, and 13 authorized patents.

2. Contact Information

Office telephone：86-021-34293460

E-mail：wzhou60@shvri.ac.cn or zhouwen60@126.com

3. Selected Papers

[1]. Ye W.C., Tang Q., Zhou T.T., Zhou C., Fan C.C., Wang X.Y., Wang C.M., Zhang K.Y., Liao G.C., Zhou W. Design, synthesis and biological evaluation of the positional isomers of the galactose conjugates able to target hepatocellular carcinoma cells via ASGPR-mediated cellular uptake and cytotoxicity. Eur. J. Med. Chem. 2024., doi.org/10.1016/j.ejmech.2023.115988.

[2]. Long Q.S. ^#, Zhou W., Zhou H.B., Tang Y., Chen. W.,* Liu Q.,* Bian X.Y.* Polyamine-containing natural products: structure, bioactivity, and biosynthesis, Nat. Pro. Rep., 2024, doi.org/ 10.1039/D2NP00087C.

[3]. Lu Y.^#, Guan T.^#, Wang S.B.^#, Zhou C., Wang M.Z., Wang X.Y., Zhang K.Y., Han X.G., Lin J.C., Tang Q., Wang C.M.* and Zhou W.* Novel xanthone antibacterials: Semi-synthesis, biological evaluation, and the action mechanisms, Bioorg. Med. Chem., 2023, doi.org/10.1016/ j.bmc.2023.117232.

[4]. Chen W.M.^#, Zhou C.^#, Chen J.S., Wang M.Z., Zhou F., Wang C.M.*, Zhang X.*, Zhou W.* Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives, Bioorg.Chem., 2021, doi.org/10.1016/ j. bioorg. 2021.105515, 2022. 119, 105515.

[5]. Zhou C.^#, Ye W. C.^#, Cao Y.J.^#, Wang M.Z., Qi D.X., Liao G.C., Li H.K., Huang W.P., Chen W.M.* Wang X.Y.,* Zhou W,* A gulose moiety contributes to the belomycin (BLM) disaccharide selective targeting to lung cancer cells, Eur. J. Med. ，2021 Chem. doi.org/10.1016/j.ejmech.2021.113866.

[6]. Wang M.Z. ^#, Chen W.M.^#, Chen J.S., Yuan S.S., Hu J.J., Han B.X., Huang Y.H.*, Zhou W.* Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies, Eur. J. Med. Chem. 2021, doi.org/10.1016/j.ejmech.1021.113487.

[7].He X.G., Li M.L., Ye W.C., Zhou W.* Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC), Bioorg. Chem. 2021, 107, doi.org/ 10.1016/j. bioorg.2020.104574.

[8]. Chen P.^#, Wang S. B.^#, Cao C.Y.^#, Ye W.C., Wang M.Z., Zhou C., Chen W. M., Zhang X., Zhang K.Y., Zhou W.* α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship, Bioorg. Chem.  2021, doi.org/10.1016 /j.bioorg.2021.105295.

[9]. Fu K.S., Bai Z.F., Chen L.L, Ye W.C., Wang M.Z, Hu J.L, Liu C.H,^* Zhou W, *Antitumor activity and structure-activity relationship of heparanase inhibitors: recent advances, Eur. J. Med. Chem. 2020, 202:112221.

[10]. Li M.L.^#, Ye W.C.^#, Fu K.S.^#, Zhou C., Shi Y.H, Chen W.M., Hu J.L., Jiang Z.L. *, Zhou W.* Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis, and in vitro and in vivo antitumor evaluation. Eur. J. Med. Chem., 2020, doi.org/10.1016/j.ejmech. 2020, 112509.

[11]. Zhou L.^#, Chen. W.M.^#, Cao C.Y.^#, Shi Y.H., Ye W.C., Hu J.L., Wang L.L.*, Zhou W.* Design and synthesis of α-naphthoflavone chimera derivatives able to reverse cytochrome P450 CY1B1 (CYP1B1)-mediated drug resistant via targeted CYP1B1 degradation, Eur. J. Med. Chem. 2019, doi.org/10.1016/j.ejmech. 2019.112028.

[12]. Cui J.H., Meng Q., Zhang X., Cui Q., Zhou W.*, Li S.S.* Design and synthesis of new naphthoflavones as CYP1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression, J. Med. Chem. 2015, doi.org/10.1021/acs.jmedchem.5b00265.

4. Selected Patents

[1]. Methods for enzymatic chemical synthesis of structurally defined heparin sulfate oligosaccharides, 2021, Patent NO, CN ZL201810539159.09.

[2]. The preparation method for 3-O-carbamoyl mannose donor derivative, bleomycin disaccharide and its precursor. 2021, Patent NO, CN ZL2018105770218.

[3]. The preparation method for 2-hydroxygulose receptor derivative, bleomycin disaccharide and its precursor. 2021， Patent NO, CN ZL2018105770932.

[4]. Enzymatic synthesis and application of heparin sulfate and FK506 conjugates, 2020，Patent NO, CN ZL201810 444478.1.

[5]. A preparation method for substituted benzyl or substituted phenyl-β-D-hexuronic acid glycoside, 2020，Patent NO, CN ZL201810503213.4